Biocom LifeLines - Fall 2014

LifeLines For the Southern California Life Science Community

7

Before Congress and the Legislature Wind Down, Activity Heats Up

11

An Update on Biocom’s Strategic Initiatives

16

Fatigues to Lab Coats

From Project to Passion: Diving into a New Patient Population VOLUME 23, ISSUE 3 F a l l 2 0 1 4

Dexcom, Inc.

AltheaDx

218,000 SF Tenant Representation

Arcturus Therapeutics

60,000 SF Tenant Representation

Exterior View @ South Facade TORREYANA

San Diego, CA

Biocom

10,000 SF Tenant Representation

10,900 SF Tenant Representation

Cubist

Genomatica

45,000 SF Sublease Disposition

Verenium / BASF

70,000 SF Tenant Representation

70,000 SF Tenant Representation

April 3, 2013

Mirati Therapeutics 18,000 SF Tenant Representation

Genzyme / Sanofi 64,000 SF Sale Disposition

IN THIS ISSUE 2

Cover Story: From Project to Passion: Diving into a New Patient Population

7

Public Policy : Before Congress and the Legislature Wind Down, Activity Heats Up

9-10 Members in Action: BIO International,

California LIfe Science HR Conference, Biocom PAC Legislators and Candidates Reception, DeviceFest

11 An Update on Biocom’s Strategic Initiatives 12 Guest: Venture Capital Outlook Optimistic as IPO, M&A Streaks Continue

14 Events: Refelections 15 STEM Education Soars as the Festival Prepares for 2015

16 Fatigues to Lab Coats 18 Biocom Purchasing Group: A Renewed Focus on Scientists

20 Premium Member Spotlights:

Ajinomoto Althea, Conatus Pharmaceuticals, Mintz Levin, Praxair, VWR

22 Biocom Board and Committees 23 Biocom Membership

E D I TO R : Jennifer Landress CO P Y E D I TO R : Josh Baxt DESIGN & LAYOUT: Arlene Arreola VOLUME 23, ISSUE 3

Biocom, a member driven organization is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your company with saving money, advocacy, increased visibility, networking opportunities, capital development and workforce development.

WELCOME

By Joe Panetta, President and CEO, Biocom

OUR BUSY SUMMER

Welcome to the fall 2014 edition of Lifelines. I am writing this in Biocom’s temporary offices, where we are eagerly anticipating completion of our new member-friendly offices on Torrey Pines Mesa.

It has been a busy summer, as we plan for our final move next February. We look forward to welcoming you to our new facility, which will provide an improved space to meet with newly formed start-ups, established pharma and device companies and the many research entities that will surround us. I again want to thank Alexandria Real Estate and our board member Brent Jacobs of Cushman Wakefield for creating this exciting opportunity.

Since our last issue, we have enjoyed a very successful BIO 2014 annual convention.

During the convention, more than 14,000 people came to San Diego from across the globe to network, enjoy panel presentations and hear from such prominent leaders as former Secretary of State Hilary Clinton, Sir Richard Branson and Governor Jerry Brown. By all accounts, it was one of the most successful BIO conventions ever, led locally by our board members Magda Marquet and Steven Mento.

But it could not have been so successful without the help of our business partners in San Diego. In particular, I’d like to thank the San Diego Convention and Visitors Bureau and the San Diego Regional EDC for their support. Finally, Mayor Kevin Faulconer was tireless in meeting with foreign delegations and enthusiastically addressing the convention with a rousing welcome from San Diego’s life science community.

In this issue, we celebrate some not-so-familiar aspects of Biocom’s efforts, as well as those of our extended life science community. In our cover story, Cammy Duong of Canale Communications again joins us, this time to focus on the research being done on diabetes and aging, using dolphins as study subjects, at the National Marine Mammal Foundation.

If you attend Biocom’s Annual Dinner on November 20, you will have a chance to hear more about this cutting-edge research.

As a reminder of why we go to work each day in this industry, as we plan for our upcoming annual dinner, our Events Department takes a look at some of the amazing patient advocates we’ve featured over the years.

Much of our work on the public policy front supports our large therapeutic and medical device membership. However, this month our Public Policy VP Jimmy Jackson discusses our efforts to better inform the public and legislators about the facts surrounding genetic modification of salmon and other fish. In this case, calls for labeling and more health effects studies were not supported by the scientific data.

In addition, our Purchasing Group story focuses on some of the different programs we offer to help scientists. Our Biocom Institute column will tell you about Fatigues to Lab Coats, our program for veterans entering the life science industry. Also, while many members have participated in our annual San Diego Festival of Science & Engineering, we also offer STEM and other educational programs for teachers and students leading up to next years’ Festival.

The capital markets have been very good to our life science companies over the last two years, with the IPO market at an all-time high for our industry. But the real life-blood of our success in Southern California has come from active VC investing. Our roving reporter, Mandy Jackson returns this month with a story on recent venture transactions and discusses some of the capital formation programs that Biocom offers our members.

I look forward to our continued success as an industry, and hope to see you soon at one of our many Biocom functions.

WWW.BIOCOM.ORG Biocom LifeLines Fall 2014

1

COVER STORY

By Cammy Duong, Canale Communications

From Project to Passion: Diving into a New Patient Population Coming Together to Accomplish Something Bigger Than Ourselves In the 1960s, Sam Houston Ridgway, D.V.M, Ph.D., an experienced Air Force veterinarian, was called on by the Navy to provide medical care for dolphins, which were being studied for their speed and agility. This interaction between humans and marine mammals soon blossomed into a partnership to locate undersea mines, recover lost objects and find enemy divers. The

2

Biocom LifeLines Fall 2014

partnership helped researchers learn about marine mammal health and intelligence, which has been described in more than 1,000 peer-reviewed scientific publications.

More than 40 years down the road, Dr. Ridgway’s fascination with dolphins led to the founding of the National Marine Mammal Foundation (NMMF). As a nonprofit, the NMMF aims to protect the health and welfare of marine mammals and humans through research, conservation and education.

The NMMF’s research, an extension of their work with the Navy Marine Mammal Program (MMP), led to the establishment of a dream team of experts for the foundation’s scientific advisory board. Led by Gregory Poland, M.D., director of the Vaccine Research Group and the Mary Lowell Leary Professor of Medicine and Infectious Diseases at Mayo Clinic, the board includes experts from the Salk Institute for Biological Studies, the Centers for Disease Control and Prevention, the University of California, San Diego, Duke University, Stanford University and the University of Minnesota.

The foundation’s research has significant applications to human health. “After almost seven years, we have reached a critical tipping

COVER STORY point with our marine mammal translational research that is aimed to benefit both human and dolphin health,” said Stephanie Venn-Watson, D.V.M., director of the Translational Medicine and Research Program at NMMF. “Today, we have momentum, excitement and a growing community of human health physicians and scientists in diabetes, aging and infectious diseases joining our dream team. This growth in world-renowned scientists is being paired with sound science and potential breakthroughs in understanding how dolphins may help prevent, manage and treat diabetes in humans.”

The foundation’s long-term relationship with marine mammals has led the dolphins and sea lions of the program to willingly cooperate by providing blood samples, ultrasounds and CT scans, as well as participating in hearing tests.

This allows researchers to gain greater insights into their overall wellbeing.

For example, given a simple command when it’s time to have their blood drawn, dolphins are responsive by flipping their tails up so researchers can draw blood for research.

traditional researcher and mouse relationship that exists within life science laboratories. Researchers look at dolphins as a new patient population and experiments are based on evaluating the dolphins’ natural physiological state, as opposed to manipulating it.

In 2010, the NMMF made a remarkable discovery that made headlines around the world – dolphins may hold the key to curing diabetes in humans.

“Our journey started with an amazing and unexpected finding that dolphins, before they ate their breakfast, had blood value changes similar to people with diabetes, versus later in the day, after they ate, their blood changes mimicked those in people without diabetes,” said Dr. Venn-Watson. “This led us to believe that dolphins could have a switch that could turn a diabetes-like state on and, more importantly, off.”

The foundation discovered that dolphins can display prediabetes-like symptoms, but never progress to Type 1 or Type 2 diabetes. They’re working with prominent local research institutions, such as the Salk Institute of Biological Studies, to expand on these findings.

One element that has been helpful in this research is an incomplete sequence of a dolphin genome, which revealed that genes related to glucose metabolism are similar between dolphins and humans. Additionally, the foundation has discovered that humans are more similar in many physical characteristics to dolphins than they are to chimpanzees, and that as dolphins get older, they exhibit common disease states with humans, such as high triglycerides, chronic inflammation, and high cholesterol.

The foundation hopes to partner with an organization to fund the sequencing of the remaining dolphin genome to see what other similarities may exist between humans and dolphins.

The Other Branches of Focus While diabetes is the foundation’s primary focus, their work spans into other sectors, such as aging and infectious diseases.

Current research conducted in atherosclerosis by Evan Muse, M.D., Ph.D., KL2 Clinical Scholar and Cardiovascular Research Fellow at the Scripps Translational Science Institute, may illuminate the relationship between metabolic syndrome and vascular disease in dolphins and could translate into cardiovascular

The Breakthrough While the Navy Marine Mammal Program is not well known to the public, the Navy is allowing limited, escorted access to its facilities to raise awareness about the NMMF and its research.

The 80 dolphins housed at the facility work in open waters and are monitored around-the-clock by experienced veterinarians who have established rapport with the marine mammals.

The research and environment differ significantly from the

Biocom LifeLines Fall 2014

3

COVER STORY over 10 years compared to wild dolphins assessed from 1994 to 2003. During 2013, 30 percent of the MMP dolphin population was older than 30 years, with the oldest dolphin being 52 years – demonstrating that a high proportion of dolphins in this managed population are surviving beyond reported expected ages of free-ranging dolphins1.

disease prevention in humans.

On the infectious diseases front, David Relman, M.D., The Thomas C. and Joan M. Merigan Professor in the Departments of Medicine and of Microbiology & Immunology at Stanford University, has been looking into the bacteria (microbiome) that make their homes in marine mammals.

“What happens to dolphins in the water may be an indicator of changes in the natural environment that will have an impact on us as well,” said Dr. Relman. “Every animal has their own story on what their microbiome does for them, but so far we have had very little information on mammals that live in the sea. That’s interesting to me because there could be fundamental differences in the microbiomes of animals that choose to call the sea their home as opposed to those that live on land.”

Part of the reason the marine mammals make such good subjects for these studies is because of how well they are cared for. The foundation’s emphasis on providing the utmost care for the Navy’s and other marine mammals is driven by passion and a primary mission. The marine mammals are further ensured the best care through the program’s accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and routine animal care and welfare reviews by the Navy’s Bureau of Medicine and an Institutional Animal Care and Use Committee.

With such protocols in place, the foundation’s population of marine mammals is the longest surviving. A recent study published in the Journal of the American Veterinary Medical Association found that in a population of 103 dolphins living under the care of the United States Navy Marine Mammal Program (MMP) assessed from 2004 through 2013 had a median age of death increase by

4

Biocom LifeLines Fall 2014

The Challenges As the foundation continued to share its research, the biggest hurdle was getting the scientific community on their side.

“The primary challenge is one of scientific silos,” said Dr. Poland, Director of the Immunization Clinic and the Director of the Program in Translational Immunovirology and Biodefense at the Mayo Clinic. “The veterinary and human medical and research communities, surprisingly, have not learned from each other to the degree that would actually benefit both camps. Our job will be to join in the increasing chorus of voices and professional organizations that do recognize the importance of ‘one health’ and promote its importance to scientists, funding agencies and the public. We will all be better off and more quickly advance the science and translate that into medical advances when we work together and learn from one another.”

Another challenge, noted earlier, is not having access to the full dolphin genome. Having the full genome would be a giant step towards translating the findings from working with marine mammals into something substantial for the human population.

The Future As we wait for a life-changing breakthrough that could revolutionize diabetes care, the statistics remain the same – more than 29 million people have diabetes in the United States and 450 million will fall victim to the disease by the year 2030, according to the American Diabetes Association.2 Given this global health crisis, the foundation will dedicate significant resources towards diabetes over the next five years.

A recent two-day, TED-like clinical meeting hosted in San Diego by the Office of Naval Research, the MMP, and the NMMF brought 50 world-renowned researchers from 38 nonprofit, academic and government organizations from all over the country to discuss how to improve marine mammal health, as well as potential applications to human health. At the meeting, the researchers helped establish

COVER STORY a five-year strategic plan with four big focuses on how to prevent, manage and treat diseases in marine mammals, many of which are also present in humans. This bold program seeks to: 1. Find the diabetes “off” switch 2. Cure diabetes with a diet of fish 3. Stem the negative effects of high blood sugar 4. Monitor diabetes using breath Other research priorities include geriatric health and Alzheimer’s disease.

The foundation is also looking at its longest surviving sea lion population and monitoring their health.

This study was prompted by an unusual event in 2013, when more than 1,000 dead sea lion pups were washed ashore in San Diego.

“By taking marine

mammal research into the digital era and incorporating these lessons in humans, we can apply it to a whole new population,” said Dr. Evan Muse. “The crossover is the dolphin version of the ‘quantified self’ in understanding basic physiology.”

As a result of greater visibility, the foundation has two patents pending for research tied to nutrients in fish consumed by the dolphin and detecting diabetes technology through breath.

The research conducted by the National Marine Mammal Foundation is not only diving into the commonalities between dolphins and humans and translating that into greater insights and better treatments for both species, it’s also giving hope to families impacted by diabetes.

References 1. Venn-Watson, S., Jenson, E., Smith, C., Xitco, M., Ridgway, S. (2011) Assessing Health of dolphin populations.

Journal of the American Veterinary Medical Association.

238(3):356-60. DOI: 10.2460/javma.238.3.356 2. American Diabetes Association (ADA). (2014, June 10). Statistics About Diabetes. Retrieved October 1, 2014, http://www.diabetes.org/diabetes-basics/ statistics/?loc=db-slabnav 3. Photos are credited to the United States Marine Mammal Program

PMS 382

i3, LA JOLLA

iconic . inspiring . innovative

858.410.1252

PUBLIC POLICY

By Jimmy Jackson, Vice President of Public Policy, Biocom

Before Congress and the Legislature Wind Down, Activity Heats Up Traditionally, the third quarter of the year is by far the Biocom Public Policy department’s most active time. This year did not disappoint.

The legislature is now adjourned, and once again, Biocom had an incredibly successful year at the state level. In this session, Biocom supported 16 bills, and opposed nine. Of these, six were high priority for staff and Biocom’s contract counsel. All six highpriority bills had favorable outcomes for Biocom members, having been defeated or amended sufficiently for Biocom to remove our opposition. Once again this year, no bills opposed by Biocom were signed into law. In fact, none even got to the governor for his signature.

Major victories came on bills concerning unnecessary food labelling of products derived from a genetically modified source; prescription and sharps take-back schemes, which sought to place all financial and logistical responsibility on manufacturers; and a bill that would have shut down companies in California doing important research on salmon and trout species. A more comprehensive report can be found in the Public Policy section of the Biocom webpage.

Assembly Bill (AB) 504 (see cover story in the September 11, 2014, edition of Biocommunique for more details) was one of those occasions where the San Diego delegation worked together for a favorable result. Very late in this year’s session, the bill was significantly altered. In its revised form, it would have banned research or production on transgenic salmonids (salmon, trout and many other freshwater fish species) anywhere in California (including labs), even though no production of such fish has ever occurred in state waters.

Biocom was contacted by a member company that would have been adversely affected by this ban. In fact, the company’s core business would have no longer been allowed in California. The company had already been rebuffed in its attempts to secure changes in the bill and knew it was coming to Biocom very late in the process. Biocom and BIO approached the author, but were unable to convince him to exempt research by private companies.

Biocom and BIO spoke to staff for three key San Diego legislators: Senator Marty Block and Assemblyman Brian Maienschein, who represent the districts where the facility resides, and Assembly Speaker Toni Atkins, who has a long history of support for the life science industry. The three legislators all reached out personally to

the bill’s author, after which he reversed course and worked with BIO and Biocom to develop language that satisfied all stakeholders.

In Washington, D.C. Federally, Biocom worked tirelessly to address serious concerns over legislation that could have made it more difficult for patent holders to protect and enforce their intellectual property rights.

Thanks to aggressive and coordinated efforts by the biotech and pharmaceutical industries, debate over patent litigation reform collapsed over the summer and dangerous bills were successfully removed.

These past months were also marked by the 21st Century Cures Initiative, a massive Congressional enterprise that intends to reform and boost our innovation ecosystem. The House Energy & Commerce Committee – the committee overseeing the initiative – held a series of hearings and roundtables featuring federal officials, such as NIH Director Francis Collins and FDA Commissioner Margaret Hamburg. Biocom submitted comments highlighting the importance of digital health technologies and remains available to work with the committee as they draft comprehensive legislation.

Biocom also continues to advocate for increased funding for the NIH, whose budget has been flat for the past decade. Most recently, Biocom joined more than 300 organizations in our nation’s capital to urge Congress to make a sustained investment in medical research.

Locally, Biocom worked with the JOBS Coalition to ensure enactment of a compromise agreed to by key stakeholders on both sides of the linkage fee increase issue. This compromise exempts R&D properties from future increases in the fee for the length of the agreement. We are also increasing our engagement with Mayor Kevin Faulconer and members of the City Council.

Jimmy Jackson is the Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.

Biocom LifeLines Fall 2014

7

GLOBAL REACH, LOCAL SUPPORT. SINCE 1852.

At VWR, we enable science by supplying critical laboratory products,equipment and services, offering the best product choices, including the Exclusive VWR Collection, from premier manufacturers to customers around the globe.

We are committed to providing effective, efficient solutions for all your Life Science needs. VWR is advancing scientific innovation to make your work faster, easier and more accurate, so you can focus on what’s truly important: discovery.

MEMBERS IN ACTION

BIO INTERNATIONAL CONVENTION

BIO INTERNATIONAL CONVENTION 2014: Clockwise from left: Joe Panetta welcoming conference delegates at the opening plenary session, Gail Maderis of BayBio presenting the joint statewide Economic Impact Report, Jim Greenwood of Bio interviewing Hillary Rodham Clinton during the packed plenary lunch, the California Pavilion, which was a popular hot spot during the convention.

CALIFORNIA LIFE SCIENCE HR CONFERENCE CALIFORNIA LIFE SCIENCE HR CONFERENCE. Attendees participated in “speed-dating” style session of the latest hot topics and sizzling issues. Here, Robin Toft is leading the group in a roundtable discussion on recruiting and sourcing for HR Executives; Brittney Grosse of Synthetic Genomics, Natasha Bowman of Synthetic Genomics, Brian Riehle of Biophase Solutions.

Biocom LifeLines Fall 2014

9

MEMBERS IN ACTION

BIOCOM PAC LEGISLATORS AND CANDIDATES RECEPTION BIOCOM PAC LEGISLATORS AND CANDIDATES RECEPTION: Clockwise from left: Sedrick Spencer of Celgene, Congresswoman Susan Davis and Matthew Schumaker of Celgene; Amy Zajac of Genentech, County Supervisor Greg Cox, Speaker of the Assembly Toni Atkins, Sandra Pizarro of Genentech and Don Fitzgerald of Genentech; Tom Boyer of Novo-Nordisk, John Schlatter of Takeda Pharmaceuticals and Assemblyman Brian Jones; Speaker Toni Atkins, Ritchard Engelhardt of BayBio, Thelma Harris of GSK, Kathryn Crossin of Promosome and Assemblywoman Shirley Weber.

DEVICEFEST

DEVICEFEST: Pete Shagory of Cardinal Health, Benjamin Perkins, of Ernst & Young, John Mattison of Kaiser Permanente Southern California and Nicholas C. Manusos of GE Ventures ; John Mattison of Kaiser Permanente.

10

Biocom LifeLines Fall 2014

MEMBERSHIP

By Kira Jenkins, Director of Membership, Biocom

An Update on Biocom’s Strategic Initiatives I am often reminded of the many ways our members are improving health in our region and across the world. This industry really moves at warp speed, which is why Biocom has made a concerted effort to hold regular, in-person meetings and calls with our member companies. We know that your needs are constantly shifting, and Biocom stands ready to help meet those changing needs.

In response to the needs of many of our members, Biocom has launched several new initiatives to propel this industry forward on the world stage. Here are some updates on each exciting new group.

Biocom Concierge Our members are constantly inquiring about specific services, and fortunately, they look to us as a resource. We thought we would make this process even easier for our members by building a website. Biocom Concierge (www.BiocomConcierge.org) offers a user-friendly and searchable interface, providing recommendations on trusted service providers in many sectors, such as financial, lab, legal, operations and professional services. This website was launched three months ago and has become a huge asset for many of our members. As always, we highly recommend that our members use services provided by other Biocom members.

CRO Initiative Here in Southern California, we have seen an extraordinary growth of outsourcing (or near-sourcing) in the life science industry with the expanding number of contract research organizations in the region. Since the inception of our CRO/CMO committee, we have grown from having 30 companies in this space to more than 90.

We continue to hold six events a year, educating sponsors on timely topics covering all aspects of drug development. A best practice series for our CRO/CMO members and discipline-specific networking receptions allow scientists to meet with CRO’s that can assist them with their company’s needs.

San Diego has been very lucky to have a number of key tradeshows in town, including AACR, AAPS, BIO and DIA. In addition to exposing our CRO’s on a local level, we have built awareness for our members on a global level by participating at these events and disseminating a map of our CROs and their core competencies to attendees.

digital health companies participating. Our goal is to create more awareness for this sector, which is working to revolutionize healthcare. We have held a roundtable discussion with Congressman Scott Peters, helping our members educate him about their companies and the roadblocks they face.

We also held a breakfast meeting, during which representatives from Kaiser Permanente shared some of their unmet needs.

Attendees were then encouraged to present their company’s mobile health/remote care solutions to a Kaiser panel. They will receive invaluable one-on-one feedback about their products from one of the largest healthcare providers in the world.

We will also be educating policymakers at our DC Fly-In in December. Meetings are being planned with the FDA, Veterans Administration, and Office of the National Coordinator for Health Information Technology. There are even more exciting things to come in 2015.

Veterans Initiative This initiative was formed to address the disconnect between our life sciences industry and San Diego’s veterans community and foster communication between the two groups. Our committee is working to bring veterans together with HR representatives, as well as creating a networking community for veterans who are currently employed within our life science community, by hosting professional networking mixers.

We have launched a mentorship program, during which nine veterans have been exposed to our community by caring mentors.

Mentees have also been given the unique opportunity to go through a mock interview with some of our industry’s top talent recruiters.

The mentees were then provided invaluable feedback to use when applying for positions. Recruitment into this program will begin again in 2015.

Having served on the membership team at Biocom for the past nine years, I have been fortunate to work with many of you on numerous initiatives. Our mission remains the same and our commitment to meeting the needs of our members has never been stronger. Biocom is focused on you, our members, and we look forward to spending more time meeting and talking in 2015.

Kira Jenkins is the Director of Membership for Biocom and also formed and spearheads Biocom’s Digital Health and CRO committees.

Digital Health Initiative This new initiative is off to a strong start, with more than 20

Biocom LifeLines Fall 2014

11

GUEST

By Mandy Jackson, West Coast Editor, SCRIP Intelligence

Venture Capital Outlook Optimistic as IPO, M&A Streaks Continue Venture capital investors who focus on the life sciences industry are optimistic about the outlook for early-stage funding. The optimism is fed by the pace of returns on prior investments, as biotechnology companies exit venture fund portfolios via initial public offerings or mergers and acquisitions. The exits make limited partners more willing to back new venture capital funds that will fund even more biotech startups and follow-on financings.

But the VC optimism is tempered by realism. Venture capitalists know the IPO and M&A boom won’t last forever.

Alongside the San Francisco Bay Area and Boston-Cambridge, San Diego remains a magnet for venture capital investment in life science companies.

“There are two things about San Diego: It is an early innovation, discovery place. We’re known for crazy big ideas that sometimes work out,” Avalon Ventures managing director Jay Lichter said.

He pointed to institutions like the Sanford-Burnham Medical Research Institute, the Scripps Research Institute, La Jolla Institute for Allergy & Immunology and the University of California, San Diego as the source of a lot of biotech innovation in the region.

“The other thing that’s special about San Diego is the talent base,” Dr. Lichter added. “Most of the people who live here want to stay here, so we get some incredible talent, including both science and business people, who are committed to building biotechnology in San Diego.”

Avalon and its big pharma partner GlaxoSmithKline recently invested up to $10 million each in two startups that will be headquartered in San Diego, Silarus Therapeutics and Thyritope Biosciences. Avalon and GSK invested in the two biotech firms, whose technology was licensed from the University of California, under the partners’ April 2013 agreement to co-invest up to $495 million in 10 companies spun out of academia.

On the other end of the life science startup spectrum, local biotech veteran Jeff Stein attracted $32 million in Series A funding in June for a new antifungal drug development company called Cidara Therapeutics. Dr. Stein was president and CEO of the antibiotics-focused company Trius Therapeutics when it was sold to Cubist Pharmaceuticals for up to $818 million in 2013.

“We have seen a very robust inflow of deals in 2014, which I think reflects investment in public markets and the new funds raised,” Canaan Partners general partner Wende Hutton said.

Canaan and Avalon both raised their most recent venture capital funds in 2012 – a total of $200 million and $201.6 million, respectively, for life science and technology companies.

New funds in 2014 include: a $400 million effort from ARCH Venture Partners, at least half of which will be invested in biotech companies; a $450 million high-tech and health care fund raised

by Venrock; and a $500 million biotech-focused fund raised by Sofinnova Ventures.

Biocom began hosting Venture Days in 2010 to connect venture

12

Biocom LifeLines Fall 2014

capital investors with Southern California life science companies in one-on-one meetings. Canaan, Avalon, Sofinnova, Orbimed, 5AM Ventures, Frazier Healthcare Ventures, MedImmune Ventures, SR One, Astellas Venture Management and Aisling Capital are all past participants. Most recently, Biocom arranged meetings on October 1 for at least five companies and two universities with SR One, GSK’s venture capital arm.

The willingness of corporate VC firms, like SR One, to invest in early-stage biotech and the availability of capital from new venture funds provide welcome relief for the VC community. Both are needed to create syndicates that invest in biotech company funding rounds.

“The environment certainly felt stressed about two or three years ago when syndicate building had a thin set of players, because many were focused on reinvesting in their portfolios,” Hutton said.

“But with a very broad-based M&A market and a very broad-based IPO market, we’re finding that venture players are able to raise money. Putting together syndicates is actually more competitive.”

Eighteen of the 23 venture-backed IPOs during the third quarter of 2014 were life sciences IPOs. The July-to-September period marked the sixth consecutive quarter for double-digit IPO listings in the life sciences sector, according to the National Venture Capital Association (NVCA).

Fifteen out of 119 venture-backed M&A deals during the third quarter involved life science companies. By comparison, there were 11 biotech or medical device M&A transactions in the second quarter and 18 venture-backed deals during the third quarter of 2013, according to NVCA. But while money is flowing more freely into life science startups, venture firms remain focused on quality of investments rather than quantity.

“We are very careful when we assess a potential asset, because we know these robust IPO and M&A markets will come and go.

This window may extend for a while or it may last only for certain companies,” Hutton said.

Canaan and other VC firms are keeping an eye on San Diego, however, while venture cash is still flowing into biotech.

“San Diego has maintained a very nice pipeline of biopharma companies. The community seems to be in a resurgence that parallels the overall marketplace, which is great to see,” Hutton said.

Mandy Jackson is the West Coast Editor of Scrip Intelligence, a biopharma news website, which can be found at www.scripintelligence. com.

February 25-26, 2015 The Lodge at Torrey Pines

Biocom’s fifth annual Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives and business development professionals from leading pharmaceutical and biotech companies. The conference will include case study presentations, individual company presentations, one-on-one meetings, and numerous networking opportunities.

Confirmed Speakers: »Karen Bernstein, Chairman & Editor-in-Chief, BioCentury »Bharatt Chowrira, Chief Operating Officer, Auspex Pharmaceuticals »Iain Dukes, SVP, Licensing & External Science, Merck »George Golumbeski, Senior Vice President of BD, Celgene »Mike Grey, President & CEO, Lumena Pharmaceuticals Inc., Venture Partner at Pappas Ventures »Chris Haskell, Head, US Science Hub, Global External Innovation & Alliances, Bayer Healthcare »Rich Heyman, CEO, Aragon Pharmaceuticals »Adam Keeney, Global Head, External Innovation, Sanofi »Heath Lukatch, Partner, Novo Ventures »Carole Neuchterlein, Head, Roche Venture Fund »Ed Saltzman, President, Defined Health »Bob Smith, Senior Vice President, Pfizer »Corrine Savill, Head of Business Development and Licensing, Novartis »Jack Tupman, Vice President, Corporate Business Development, Eli Lilly

www.Biocom.org

EVENTS

By Ashleigh Berry, Associate Manager of Events

Reflections At Biocom, we plan more than 75 events each year, ranging from conferences and breakfast meetings to receptions and galas. It’s easy to get caught up in the logistical processes of each event; i.e. food and beverage, venue selection, décor, panel preparation, etc.

However, we often work with extraordinary speakers, reminding us why we host these events in the first place and why I feel privileged to plan them.

Working with a patient advocate reminds us all why it is so imperative that we come together as a life science community. As supporters, devotees and representatives, patient advocates truly have a voice in the life sciences industry, impacting the extensive research being done in our community. As I reflect on the patient advocates Biocom has been lucky enough to feature, I feel humbled to have met and worked with such inspiring individuals.

Biocom members heard from author and neuroanatomist, Jill Bolte Taylor at our 2013 Annual Celebration of Life Dinner. Jill suffered a stroke, and as a brain scientist, was able to watch and take notes as her brain functions slowly shut down one by one. As a survivor and patient advocate for stroke recovery and aphasia, Taylor told moving stories about her recovery and learning how to walk and talk all over again. The audience was captivated, as was I, but what I remember most about that day was how excited Jill was to be visiting San Diego from Indiana and relaxing at the beach all day. Her enthusiasm and appreciation for life, despite all her obstacles, was truly inspiring.

We were fortunate enough to hear from patient advocate John Crowley, at our 2012 Celebration of Life Dinner. Two of Crowley’s children, Megan and Patrick, were diagnosed with the neuromuscular disorder Pompe’s disease. Upon receiving this devastating news, Crowley left Bristol-Myers Squibb to pursue a cure for Pompe’s Disease.

Crowley shared a moving video of his two children. Unfortunately, there was a technical glitch with the video. As an event planner, my first reaction was concern that my speaker was being put in an awkward situation. However, Crowley calmly waited for the video to work again and, in the meantime, continued his story. As I looked around the room, I noticed that everyone was glued to the stage as he shared his heartbreaking, yet inspiring story. No one even cared about the video glitch.

At the 2011 Celebration of Life Dinner, attendees heard from comedian Bob Saget, along with Luke Evnin, chairman of the Scleroderma Research Foundation. Luke opened the dinner by telling his story about being a scleroderma patient. Luke’s story was moving and it was encouraging to hear that his background in biotech has helped accelerate scleroderma research. In closing,

14

Biocom LifeLines Fall 2014

Bob Saget shared the saddening story of losing his sister to scleroderma, and becoming a patient advocate for the Scleroderma Research Foundation.

While most people think of Bob Saget as a hilarious comedian, it was unforgettable, and real, to see another side. For a dinner that was intended to be comic relief, there wasn’t a dry eye in the house. Hearing these two speak reminded everyone why we are in this industry in the first place.

Going back even farther, our first Celebration of Life Dinner, in 2003, featured Naomi Judd, country singer and motivational speaker. Judd shared her battle with Hepatitis C. Upon receiving this diagnosis, she started the Naomi Judd Education and Research Fund to help raise awareness about the disease. Naomi Judd is in good health today and is now dedicated to raising awareness throughout the life science community.

It is easy to see that the common theme for these events is to reflect on the success of the life sciences community, while highlighting a patient advocate. This year, we are privileged to showcase the Wilson family, as Sarah Wilson, mother of five children, shares her family’s journey and struggle with two young daughters living with type 1 diabetes. We invite you to join us for this inspirational dinner taking place on November 20.

If you have already registered for this dinner I invite you to share in the excitement on Instagram and Twitter via #BiocomAnnDinner.

Ashleigh Berry is the Associate Manager of Events for Biocom and is in charge of organizing and marketing Biocom Events.

Biocom’s Celebration of Life Dinner

November 20th Hyatt Regency La Jolla

Dr. Rudy Tanzi

Alzheimer’s Genome Project

Sarah Wilson

The National Mammal Marine Foundation

SCIENCE FESTIVAL

By Sara Pagano, Managing Director, SD Festival of Science & Engineering

STEM Education Soars as the Festival Prepares for 2015 You don’t have to be a teacher. Anyone can spark sustained excitement for science and engineering in young people. This past summer, the San Diego Festival of Science & Engineering reached out and challenged parents to engage their children with our Summer STEM (science, technology, engineering and math) program.

“Creativity, play, exploration, critical thinking and fun epitomize what STEM is all about,” says Becky, whose children Lincoln and Mia won this year’s STEM competition. “It is imperative that, as parents and as a community, we push our kids to investigate their world, ask questions, challenge themselves, and to not just dream about doing amazing things, but actually do those things. Anyone can do STEM and it is our job to facilitate the opportunities for discovery.”

Though the Summer STEM program has come to an end, the Festival is just getting started on the 2015 season.

The Bright Idea Society STEM clubs or classrooms can submit an idea for a program from concept to inception. The Festival’s education committee will choose a winning group from one elementary, middle and high school. The winners will each be awarded a $500 educational stipend to purchase materials and supplies to bring their project to fruition. In addition, they will have the opportunity to present their final project at the 2015 Expo Day, the grand finale of Festival Week, which takes place on March 21 at Petco Park.

STEM Design This competition encourages children to express their creativity by integrating art with their love of science and engineering. The Festival invites students K through college to submit a STEM design. The winner’s design will be featured on the front of the 2015 Festival Week t-shirt. The winning recipient will also receive a framed copy of their artwork, along with an educational stipend and the opportunity for their work to be seen by more than 50,000 STEM enthusiasts throughout Festival Week.

a myriad of educational activities during Festival Week. In addition, this year the Festival will allow teachers to apply for classroom supplies for STEM projects.

Nifty Fifty This program brings STEM professionals into San Diego classrooms to inspire future generations to become STEM innovators. Presenters are partnered with classrooms studying STEM topics that match their area of expertise. Many of our past presenters have said they learn as much from the experience as the students learn from them.

STEM Ambassador Pilot Program This program works with college students pursuing STEMrelated majors. Students have the opportunity to help with the Festival’s marketing campaign and become Festival Ambassadors, representing the organization in an official capacity throughout Festival Week. In addition, they will be paired with a Nifty Fifty mentor for K-12 classroom presentations. Students will be eligible for volunteer credit.

Whether you are a parent, educator, STEM professional, or all of the above, there is something for you at the San Diego Festival of Science & Engineering.

For complete details about our programs or to submit an application or sign up to be a Nifty Fifty presenter, please log onto our website at www.lovestemsd.org.

Get your pledge in early to reserve your spot on EXPO Day. Sponsorship Opportunities are now available for 2015.

Sara Pagano is the Managing Director of the San Diego Festival of Science & Engineering

We Love STEM The We Love STEM Program (formerly Adopt-A- School) has expanded to meet the community’s growing needs. The program provides teachers the opportunity to apply for bus transportation to

Biocom LifeLines Fall 2014

15

BIOCOM INSTITUTE

By Liisa Bozinovic, Executive Director, Biocom Institute

Fatigues to Lab Coats Problem Despite their obvious leadership skills, integrity and grace under pressure, veterans are under-represented in the region’s life science workforce. The industry needs a well-defined and sustainable effort to both address its need for high-quality employees and support veterans.

Hypothesis Providing relevant, life science-specific laboratory training and professional and personal growth opportunities for underemployed veterans will increase the percentage of veterans in the industry.

Tools 1. Veterans ready to learn 2. Biocom member companies ready to hire 3. High tech lab space 4. Life science laboratory skill-building program using live research projects 5. Quality science educators 6. Industry mentors 7. Transition support Methodology The Fatigues to Lab Coats training program is aimed at veterans who have a basic understanding of biology, chemistry and algebra and a genuine interest in science and biotechnology.

Incoming trainees will receive a six-month intense training in fundamental biological concepts with an emphasis on in-demand lab techniques. The goal is to teach veterans how to design and execute statistically-relevant experiments based on contemporary questions in biology and human health. In addition to learning fundamental principles of experimental biology and laboratory science, veterans will participate in literature searches and weekly journal clubs, as well as presenting relevant journal articles and weekly progress reports.

The training program is built on online theoretical science modules, standard laboratory protocols and video tutorials to prepare veterans for practical laboratory applications. The program emphasizes hands-on laboratory proficiency and modern biological concepts.

Experiments encompass microscopy, DNA and RNA extraction and quantification, bar coding and sequencing, cloning, cell culturing,

16

Biocom LifeLines Fall 2014

gene expression quantification (RTPCR/QPCR/microarrays/ RNA sequencing), protein purification and quantification (chromatography, western blots, ELISA, fluorescence), chemical analysis (mass spectrometry), basic statistics and an introduction to bioinformatics. The trainees will work on well-established research projects using model organisms, including bacteria, plants, yeast, fruit flies, nematodes, zebra fish, marine invertebrates and various eukaryotic tissues, including human samples.

Our graduates will be qualified for entry-level biotechnician positions with life science companies and have the skills to immediately contribute. In addition to relevant theoretical, technical and analytical skills, students will acquire writing and

Training for your new mission in biotech speaking skills to successfully compete for jobs in life science industry.

Input from Biocom members will ensure the program produces qualified life science employees, serving both veterans looking for work in San Diego and the growing life science industry.

Status This idea, generated from Biocom’s Veteran Initiative Committee last spring, is gaining traction. Funding efforts are in full swing, with San Diego Social Venture Partners and NSF expressing interest in our model. Stay tuned for more information and contact us if you would like to be involved.

Future Considerations In addition to Fatigues to Lab Coats, Biocom Institute is continuing the veteran career mentor program piloted this summer.

BIOCOM INSTITUTE The program exposed veterans to potential opportunities in the industry.

The pilot paired ten veterans, for four months, with ten veteran mentors already working in the industry. Mentors provided invaluable advice, coaching and connections and veterans participated in career workshops, mock interviews, industry conferences and more. This program will be expanded in 2015 and parts of it will be incorporated into Fatigues to Lab Coats.

There are a number of veterans currently working for Biocom member companies. Look for Biocom veteran member-only networking events in 2015, as veterans have expressed an interest in networking with each other.

Also in 2015, our industry-created and vetted E-learning system will be incorporated into the Fatigues to Lab Coats program to provide a deeper dive into essential business functions and an overview of drug discovery, pharmaceuticals and biotechnology.

Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR initiative.

Look for the Biocom Institute’s special features in the San Diego Union Tribune Recruitment section every 4th Sunday where we highlight veterans working in Biocom member companies, our programs and/or our job ready veterans.

Make Your Mark

in

BiotechnologY

Professional Science Master’s The Professional Science Master’s in Biotechnology from CSUSM is a degree that leads to jobs with graduates reporting a 97% employment rate at time of graduation. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry.

For more information contact us at www.csusm.edu/el/psmlifelines

HURRY! Fall 2014 Start

APPLY TODAY

PURCHASING GROUP

By Rick Fultz, Managing Director, Biocom Purchasing Group

A Renewed Focus on Scientists The road for scientists in today’s R&D race is paved with challenging market conditions and an uncertain economic environment. There is enormous pressure to produce results amongst an ever-expanding array of technologies, services and products. And as companies work to increase their bottom line, and the government tries to reduce the deficit, research and development is often the first to get cut, leaving scientists empty handed after decades in the lab.

The Biocom Purchasing Group wants to remind Southern California scientists that we’re here to help you navigate research and development trends.

This past year alone, we’ve expanded our portfolio of savings to include invaluable resources for scientists in our member companies. Together with our endorsed suppliers, we’re creating a one-of-a-kind purchasing and data-sourcing platform that will decrease stockroom inefficiencies, reduce time to knowledge and change the way you source your research models.

valuable data sources to assess biomedical lead quality. Their knowledge discovery platform, BRAIN (Bio Relations and Intelligence Network) can help researchers find reliable information in seconds, where a traditional manual search might take weeks or would simply be too difficult to attempt.

Euretos announced this fall that they have been selected as the preferred technology provider to build the first professional international data stewardship infrastructure, DataFairport, in Europe. This platform provides an incentive to share and link data between academic scientists and public-private alliances, enabling discovery from currently unlinked data.

Since the contract was signed in 2013, a number of Biocom members have already taken advantage of their one-week free trial with BRAIN. Initial focus group feedback has indicated significantly faster access to information, compelling cost savings and increased lead quality, saving scientists time and valuable resources.

VWR: VSR+ Inventory Management System This past summer, VWR announced the roll-out of their newest inventory management technology, VSR+. This cloud-based system provides 360 degree visibility to your laboratory supplies inventory, from the scientist’s bench to all stocking points in your supply chain.

Developed to meet the specific challenges faced by research organizations, VSR+ is designed to simplify procurement and inventory management for facilities of any size, including those with the most complex supply networks for research, testing and production.

VSR+ provides real-time updates on inventory across all locations and addresses today’s requirements for consumables management, leading to increased scientific productivity. Less time in the stockroom means reduced inventory overhead costs and more time in the lab.

Together with their managed services arm, VWRCATALYST and VWR can help scientists move faster and focus more on their research. From the receiving dock to the research laboratory and through production, let VWRCATALYST reduce your operating costs and create more value with services that remove some of the complexity from the day-to-day science.

Charles River For more than 60 years, Charles River has provided tailored research models and laboratory animal support services to help global partners accelerate their research and drug development efforts. And as an endorsed platinum supplier in the Biocom Purchasing Group portfolio, Charles River offers a gratis Animal Model Evaluation Program to help researchers in any phase of research, drug discovery and development assess the quality and compatibility of their models before making a commitment.

Researchers are able to select the model they want to evaluate and Charles River will provide them at no cost.

The combined strength of our endorsed providers offers solutions that advance scientific innovation in the life sciences and provide substantial cost savings and service solutions to accelerate science from discovery to production. We encourage you to take advantage of these free trials today and start realizing the advantages of having a partner in life science success.

Euretos BRAIN and FAIR Data In addition to the expanded scientific resources from VWR, Euretos brings together an unprecedented range of scientifically

18

Biocom LifeLines Fall 2014

Rick Fultz oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.

“Genalyte is focused on creating breakthroughs in disease detection and prevention, and I am proud of the work our team continues do as we grow and expand. We are a dynamic company, and are fortunate to have found a trusted real estate partner in BioMed Realty that listens and provides tailored solutions for our unique real estate needs as we grow.”

— Dr. Cary Gunn, President, CEO and Founder

tailored solutions for your growth

For more information contact Tracy Murphy at 858 207 5931

biomedrealty.com

@biomedrealty

PREMIUM MEMBER SPOTLIGHTS PREMIUM MEMBERS AbbVie Ajinomoto Althea Alexandria Real Estate Equities Arena Pharmaceuticals Bayer Healthcare Biomed Realty Trust Biospace BP Biofuels Cadence Pharmaceuticals California Manufacturing Technology Consulting Canale Communications Celgene City National Bank COI Pharmaceuticals Conatus Pharmaceuticals Cooley LLP Deloitte DLA Piper Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic J-Labs Jones Day KPBS Latham & Watkins Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive Patheon Pfizer Praxair Prometheus Laboratories PwC Thermo Fisher Scientific Unisource Solutions* VWR International Wilson Sonsini Goodrich & Rosati * New Members from May 2014 to October 2014

20

Biocom LifeLines Fall 2014

www.biomedrealty.com Name: Kevin Tremblay Job title: Senior Associate, Leasing & Development Favorite movie: The Usual Suspects Favorite book: Unbroken, by Laura Hillenbrand Favorite quote: The man who is afraid to risk failure seldom has to face success – John Wooden Favorite TV show: Tie between Breaking Bad and Mad Men Favorite restaurant or meal: Market Restaurant + Bar, Del Mar Favorite city: Paris, France Favorite actor/actress: Will Ferrell Favorite thing to do on the weekends: Take the family to the beach What CD can we find in your car: The Lion King soundtrack & Baby Einstein CDs Favorite hobby: Golf Favorite website: Instagram Favorite spot in Southern California: Catalina Island First job: A friend and I drove throughout San Diego picking up used cardboard boxes after each move was completed. We each had just received our driver’s license so we felt liberated to be able to drive all over town and get paid for it.

Favorite part of your job: The collaboration with our tenants. I find their stories and science fascinating and it is very rewarding to support them by providing real estate solutions that help achieve their goals.

If you could have another career, what would it be: GM of a NFL franchise Why did you start working in your industry: As a student in the 90s, the dot-com boom increased my interest in stocks and investments. Over time I realized I wanted to focus on something more tangible and build something I could point to in 20 years. Real estate was an obvious choice for me.interesting

www.cnb.com

Name: Adam Ratner Job title: Senior Vice President, Sr. Private Client Advisor Favorite movie: Rudy Favorite book: The Last Lion: Winston Spencer Churchill Favorite quote: “Lies, damn lies and statistics” Mark Twain Favorite TV show: Board Empire Favorite restaurant or meal: Market Favorite city: Paris Favorite actor/actress: Robert DuVall Favorite thing to do on the weekends: Hiking What CD can we find in your car: French Essential Lesson 1-5 Favorite hobby: Cycling Favorite website: The Onion Favorite spot in Southern California: Powerhouse Beach, Del Mar First job: Paperboy (The Daily Californian) Favorite part of your job: Helping clients and their families If you could have another career, what would it be: Charter Pilot Why did you start working in your industry: Unbelievably large amount of fun.

PREMIUM MEMBER SPOTLIGHTS www.dlapiper.com

Name: Lisa A. Haile, J.D., Ph.D. Job title: Global Co-Chair - Life Sciences Sector

March 2-3, 2015 San Francisco, CA This two-day, statewide industry event brings together two of the world’s largest and most productive life science clusters – San Francisco Bay Area and San Diego – to promote California as a global innovation engine.

CALBIO fosters connections between California companies and their national and international counterparts, helping them connect with investors, medical research foundations, thought leaders and innovators.

• Over 34 years of expertise with a penchant for quality, showcased via customer testimonials and publications • Detailed technical consultation on peptide and antibody design including stable isotope and radio-labelling of peptides

T +44 (0)1642 567180 F +44 (0)1642 567181 E enquiries@crbdiscovery.com

www.crbdiscovery.com

• The most comprehensive range of proprietary dyes for labelling peptides, proteins and antibodies • Licence to perform “Click” labelling of peptides and proteins from The Scripps Research Institute • Dedicated customer service updates, full project management and online antibody tracking system

lin

Lab el

17-18 Belasis Court Belasis Hall Technology Park Billingham TS23 4AZ England United Kingdom

g

tib n A

Cambridge Research Biochemicals (CRB), established in 1980, are purveyors of peptides and antibody artisans, generating the highest quality research tools for the International Life Science Industry.

odies

www.cal b i o 2 01 5 .org

e id

Pe pt

Favorite movie: Forest Gump Favorite book: The Present Favorite quote: “If you obey all the rules, you miss all the fun.” Katharine Hepburn Favorite TV show: Seinfeld Favorite meal: Bread, cheese, grapes and a nice glass of cabernet Favorite city: Florence, Italy Favorite actor/actress: Dustin Hoffman/Julia Roberts Favorite thing to do on the weekends: Exercise and spend time with friends/family What CD can we find in your car: Crosby Stills Nash & Young Favorite hobby: Horse racing Favorite website: www.google.com Favorite spot in Southern California: Torrey Pines State Park First job: Line waitress at Hot Shoppes Cafeteria (at 14) Favorite part of your job: Working with so many brilliant scientists and learning something new about science, medicine and technology every day If you could have another career, what would it be: Fashion Designer Why did you start working in your industry:I have had a love for science and medicine since I was very young and carried that through graduate school. After my post-doctoral work at Sanford Burnham, I wanted a career where I would use my love of science to specialize in another area, and chose the law.

s

BOARD OF DIRECTORS BOARD OFFICERS AND EXECUTIVE COMMITTEE: CHAIR: Magda Marquet, Ph.D., Ajinomoto Althea* VICE CHAIR: Carin Canale-Theakston, Canale Communications* CHAIR ELECT: Theodore Schroeder VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper* VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young* VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield* VICE PRESIDENT – INDUSTRY: Daniel Burgess PRESIDENT & CEO: Joe Panetta, Biocom* Scott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo Michael Boyd, AbbVie Michael Brown, Stradling Yocca Carlson & Rauth Terrance J. Bruggeman, BioTork, LLC Timothy Caulfield John M. Dunn Geoffrey S. Eich, Amgen Stephen Ferruolo, J.D., Ph.D., USD School of Law* M. Wainwright Fishburn, Jr., Cooley LLP* Don Fitzgerald, Genentech Jack Florio, Brinson Patrick Securities Gregory Fond, Sanofi Global R&D Gregory Frost, Intrexon Corp.

Alan Gold, BioMed Realty Trust Jeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & Rosati Terry Gregg, Dexcom Jason Hannon, NuVasive Richard Heyman, Ph.D. Jim Hinrichs, CareFusion Elliot Hirshman, Ph.D., San Diego State University Matthew Hudes, Deloitte LLP Guy J. Iannuzzi, Mentus David Kabakoff, Ph.D., Sofinnova Ventures Steve Kaldor, Ph.D., Quanticel Michael Kamdar Katherine Kantardjieff, Ph.D., California State University San Marcos Paul Laikind, Ph.D., ViaCyte Kevin Larkin, TherOx Jacob Levin, Ph.D., UC Irvine James Levine, Sapphire Energy

Jack Lief, Arena Pharmaceuticals, Inc.* Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.* William Molloie, PwC Paul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.* Brian O’Callaghan Kenneth Polin, Jones Day Trindl Reeves, Barney & Barney LLC* Gregory Reyes, M.D., Ph.D., Celgene Dan Ryan, Alexandria Real Estate Equities Camille Saltman, Malama Composites James Schaeffer, Ph.D., Calibr* Christophe Schilling, Ph.D., Genomatica, Inc.* Timothy Scott, Pharmatek* Martin Seidel, Ph.D., Genomics Institute of the Novartis Research Foundation Bhasker Shetty, Ph.D., Pfizer La Jolla Larry Stambaugh* Mark Stevenson, Thermo Fisher Scientific* David Webb, Ph.D.* Scott N. Wolfe, Latham & Watkins LIFE DIRECTOR: Kennon W. Baldwin, Ferguson Pape Baldwin Architects* David Hale, Hale BioPharma Ventures* Tina Nova, Ph.D., Ilumina Biocom Board Members-Ex-Officio: Sandra Brown, Ph.D., UCSD Mark Cafferty, San Diego Regional Economic Development Corporation Constance Carroll, Ph.D., San Diego Community College District Scott Lippman, MD, Moores Cancer Center, UCSD Greg McKee, CONNECT Peter Preuss, The Preuss Foundation Jerry Sanders, San Diego Regional Chamber of Commerce *Executive Committee Member

COMMITTEE LEADERSHIP Capital Development Committee* Carin Canale-Theakston, Canale Communications David Kabakoff, Ph.D., Sofinnova Ventures CRO Committee Timothy Scott, Pharmatek Environmental, Health and Safety Committee Cliff Hanna Dan Shiel, Pfizer La Jolla Facilities Committee Andy Darragh, Ferguson Pape Baldwin Architects Brent D. Jacobs, Cushman & Wakefield FDA Committee Magda Marquet, Ph.D., Ajinomoto Althea Michele Yelmene, Pharmalink Consulting

22

Biocom LifeLines Fall 2014

Intellectual Property and Patent Law Committee Michael Mueller, Conatus Pharmaceuticals Daniel Hart, Knobbe Martens Olson & Bear LLP Legislative Committee Richard Ledford April Grant, Sunovion Pharmaceuticals Medical Device Committee Noel Gillespie, Procopio, Cory, Hargreaves& Savitch Joleen Schultz, Rady School of Management, UCSD Digital Health Committee Camille Saltman, Malama Composites

Public Policy Oversight Committee* Larry Stambaugh Paul Laikind, ViaCyte Purchasing Board Committee* Jack Lief, Arena Pharmaceuticals, Inc. Scholarship Committee Bente Hansen, BenteHansen and Associates Biocom Institute Board Committee* Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.

BIOCOM MEMBERSHIP PREMIUM

California Manufacturing Technology Consulting Canale Communications Celgene City National Bank COI Pharmaceuticals Conatus Pharmaceuticals Cooley LLP Deloitte DLA Piper

Eli Lilly Ernst & Young Ferring Research Institute Fisher Scientific Foley & Lardner GE Healthcare Life Sciences Genoptix Hologic J-Labs Jones Day

KPBS Latham & Watkins Mentus Merck Research Laboratories of San Diego Mintz, Levin, Cohn, Ferris, Glovsky and Popeo NuVasive Patheon Pfizer

Praxair Prometheus Laboratories PwC Thermo Fisher Scientific Unisource Solutions* VWR International Wilson Sonsini Goodrich & Rosati

BIOTECHNOLOGY

Cebix Cell Applications Celladon Cellana Cell Signaling Technology Center for Aquaculture Technologies Chubu Technology Licensing Office* Cibus Cidara Therapeutics* Coda Therapeutics Conju-Probe Contract Biotics Crinetics Pharmaceuticals CURx Pharmaceuticals Custopharm Cypher Genomics Dart Neuroscience Definiens* Denovo Biomarkers DNAtrix* DSM Food Specialties E&B Technologies* eFFECTOR Therapeutics Elcelyx Therapeutics Electronic BioSciences eMolecules Epeius Biotechnologies Equitech Bio Eton Bioscience* Fabrus Fate Therapeutics Formex Genelux Corporation Genentech Genlantis Genoa Pharmaceuticals Genomatica Genovo Corporation GenSignia Life Sciences GlaxoSmithKline Global Medical & Research Technologies* Guangdong Consun Pharmaceutical Company GWR Instruments Halozyme Therapeutics Harbor Therapeutics Histogen Human Longevity

Huya Bioscience International IDEXX BioResearch Illumina Imprimis Pharmaceuticals Inception Sciences Inhibrx InnoPep Innovative Cell Technologies Inovio Pharmaceuticals Integrated DNA Technologies Intercept Pharmaceuticals International Stem Cell Intrepid Therapeutics Intrexon Corporation Intrinsic LifeSciences Invetech InvivoGen IRBCo. ISIS Pharmaceuticals Jaleva Pharmaceuticals J-Oil Mills JSR Micro* Kalyra Pharmaceuticals Koltan Pharmaceuticals Kyowa Hakko Kirin California La Jolla Biologics La Jolla Pharmaceutical Company Ligand Pharmaceuticals Lpath Lumena Pharmaceuticals MabVax Therapeutics Malama Composites Mast Therapeutics MEI Pharma Meritage Pharma Miltenyi Biotech Mirati Therapeutics Monsanto MultiVir* Nautilus Environmental Neothetics NeuroGenetic Pharmaceuticals NF Techno Commerce* Nitto Denko Technical Novartis Pharmaceuticals Novo Nordisk Nucelis Ocera Therapeutics Ohr Pharmaceuticals

Optimum Therapeutics Orexigen Therapeutics OrPro Therapeutics Otonomy Pacira Pharmaceuticals Panmira Pharmaceuticals Pathway Genomics Pfenex PharmAkea Polaris Group Polynoma PolyPeptide Group Predictive Biology Preventice PrimaPharm PrimeGen Biotech Primordial Genetics* Prognosys Biosciences ProSci QED Bioscience Qingdao Ming Yaotang Medical Technology* Qingdao Newsummit New Drug Public Service R&D Platform* Quanticel Pharmaceuticals Receptos Regulus Therapeutics REKA Health Rempex Pharmaceuticals Renova Therapeutics Ribomed Biotechnologies Ridgeline Engineering Roche Applied Science Rohto Pharmaceutical RQX Pharmaceuticals RuiYi Sapphire Energy* Samumed Sanofi Sciencescape* Scripps Laboratories Senju USA Senomyx SentĂŠ Seragon Pharmaceuticals SG Biofuels Sirenas Marine Discovery Solstice Biologics SoluLink

SomaLogic* Sophiris Bio Sorrento Therapeutics SOVA Pharmaceuticals Stemedica Cell Technologies Sunovion Pharmaceuticals SynteractHCR Synthetic Genomics Takeda Pharmaceuticals U.S.A. Tanabe Research Laboratories TEGA Therapeutics* Tenova Pharmaceuticals Thesan Pharmaceuticals Tocagen Tonbo Biosciences TP Therapeutics Tracon Pharmaceuticals Tragara Pharmaceuticals Triphase Accelerator Trius Therapeutics UCB US Specialty Labs Vala Sciences Vantari Genetics Vaxiion Therapeutics Verdezyne Vertex Pharmaceuticals Vet-Stem ViaCyte Vical Viking Therapeutics Visionary Pharmaceuticals* Vital Therapies Wellspring Biosciences Wildcat Discovery Technologies Xycrobe Therapeutics* Zensun USA Zogenix

AbbVie Ajinomoto Althea Alexandria Real Estate Equities Arena Pharmaceuticals Bayer Healthcare Biomed Realty Trust Biospace BP Biofuels Cadence Pharmaceuticals

Abgent Abide Therapeutics Abwiz Bio ACADIA Pharmaceuticals ActivX Biosciences Advanced BioMatrix Advanced Targeting Systems Aerie Pharmaceuticals Afraxis Agena Bioscience* AM Chemicals AMBRX Ambryx Biotechnology Amgen Amicrobe Amplyx Pharmaceuticals Amylin Pharmaceuticals AnaptysBio AndroScience Ansun Biopharma Apricus Biosciences Arcturus Therapeutics Ardea Biosciences Arrayomics Astellas Pharma aTyr Pharma Auspex Pharmaceuticals Avantgen Avelas Avidity NanoMedicines Aviva Biosciences Bachem Americas BASF BioLegend Biomatrica Biomyx BioNano Genomics Bionomics Bio Options BioSpyder Technologies BioTork BioWa Boehringer-Ingelheim Curtana Pharmaceuticals CalciMedica CannaVest Corporation CARBOGEN AMCIS

* New Members from May 2014 to October 2014

Biocom LifeLines Fall 2014

23

BIOCOM MEMBERSHIP CRO/CMO

Bend Research BioAgilytix Labs* BioAtla Bioserv Corporation BTS Research* CalChem Synthesis Cassia Cato Research Charles River Laboratories ChemDiv Combi-Blocks* Concortis Biosystems Cytelligen Davos Chemical DD Studio Denovo Biomarkers Drug Delivery Experts* Epistem

eStudySite Exon BioSystems Expertise Engineering* Explora BioLabs GENEWIZ GRAM Laboratories Hamari Chemical San Diego Research Center Huntingdon Life Sciences Integrium Clinical Research Interplex Sunbelt inVentive Health Clinical IriSys JadeBio LCMS Solutions Mediconomics* MicroConstants Molecular Response

MPI Research Neuroservice Neuro-Sys OOxesis Biotech PacificGMP PharPoint Research Pharmatek Laboratories Profil Institute For Clinical Research PSI CRO Puracyp Quadrants Scientific RetroVirox Reveal Biosciences Rho Robarts Clinical Trials Roowin* SAFC Pharma SeqWright Genomic Services

Sherpa Clinical Packaging Spaulding Clinical Research* Starfish Medical* Therapeutics, Inc. Tioga Research Toxikon Triligent International Ultimate Labs Verum.us Virapur Wax-It Histology Services WuXi AppTec* Zensun USA Zyagen

MEDIC AL DEVICE & DIAGNOSTIC

CeloNova BioSciences Celula Cliniqa Corporation ClinMet Compellon CRISI Medical Systems Critical Diagnostics Cure Care* CTK Biotech CVAC Systems Cytori Therapeutics DermTech International DexCom Diagnostic Consulting Network Dorsa Vi USA* Ellipse Technologies Emerge Diagnostics Endologix* Enigma Diagnostics Entra Health Systems Epic Sciences

Epitope Diagnostics Fallbrook Engineering FemCap Fortimedix USA Freedom Meditech GenWay Biotech Glaukos Corporation Glysens Hitachi Chemical Research Center Hygeia Medical* Ichor Medical Systems Ignyta ImpediMed ImThera Medical Inceptus Medical INOVA Diagnostics Interpreta* Interventional Spine InVision Biomedical Group Invivoscribe Technologies Ionian Technologies

Ivantis Ivera Medical KFx Medical Liferiver MARDX Diagnostics MD Revolution Micell Technologies Millennium Health Nano Imaging Services Nanomedical Diagnostics* NuFACE* Omniome* OncoSec Medical Organovo Prometheus Laboratories Qualigen Quidel Quinn Medical ReShape Medical REVA Medical Reverse Medical

ReVision Optics Ridge Diagnostics Roka Bioscience Sequenom Shire Sienna Labs Sirigen Sonendo SpectraScience Suneva Medical Tandem Diabetes Targeson TherOx Tristan Technologies Trovagene Uptake Medical Yulex

NON-PROFIT

Institute of Engineering in Medicine ISM San Diego J. Craig Venter Institute Kaiser Permanente KOTRA - Los Angeles La Jolla Bioengineering Institute La Jolla Institute for Allergy & Immunology Lawrence Family Jewish Community Center Los Angeles Biomedical Research Institute Medicon Valley Alliance MiraCosta College Biotech Program Mt. San Jacinto College PhRMA Point Loma Nazarene University Quebec Government Rady School Of Management, UCSD

Salk Institute For Biological Studies San Diego Biomedical Research Institute San Diego Blood Bank* San Diego Clinical and Translational Research Institute, UCSD San Diego Community College District San Diego Employers Association San Diego Natural History Museum San Diego Regional Chamber of Commerce San Diego Regional Economic Development Corp.

San Diego Supercomputer Center (UCSD) San Diego Workforce Partnership Sanford-Burnham Medical Research Institute Scottish Development International

Scripps Health Scripps Research Institute Swedish American Chamber Of Commerce San Diego The BioIndustry Association The Lowy Medical Research Institute (LMRI) Torrey Pines Institute for Molecular Studies UC San Diego Extension UCI’s Office of Research UCSD, Department of Bioengineering UCSD, Health Systems- Center for Occupational & Environmental Medicine* UCSD, Office of Advancement UCSD School of Medicine UCSD, Technology Transfer Office UK Trade & Investment

University of San Diego

Abbiotec Absorption Systems Accelagen Accugent Laboratories Acurian Advantar Laboratories Agility Clinical Alliance Protein Laboratories Ambit Biosciences American Peptide Company AnaBios* Annova Chem ARIANNE Atheln Beaufort CRO* Behavioral Pharma

Acon Laboratories Aethlon Medical Alphatec Spine AltheaDx America Diagnostics Applied Proteomics Astute Medical Banyan Biomarkers* BeneChill Biocept BioDx Biological Dynamics Biomerica* bioTheranostics Breathe Technologies Bruin Biometrics CareFusion Cell Idx

American Cancer Society, Border Sierra Region Battelle* CA Institute for Regenerative Medicine Calibr California Baptist University, College of Engineering California Medical Innovations Institute* California State University, San Marcos City Of Murietta CONNECT Consulate Of Canada CSU,CSUPERB Program Escondido Union High School District Human BioMolecular Research Institute

24

Biocom LifeLines Fall 2014

INDIVIDUAL Antoinette Azevedo Bernard King Carol Gallagher Donna Janson Elliot Parks Gary Friedman John Dunn John Kavanagh Julie Ames Larry Stambaugh Peter Preuss Richard Ledford

KEY PROVIDER Airgas Barney & Barney Cushman & Wakefield Oracle Health Sciences Qualcomm San Diego Gas & Electric

PROVIDER

2Connect Accelrys ADVI AER Travel* AIS Data Centers Alexander’s Mobility Services* AMN Healthcare Assay Depot Austin Commercial Beckloff Associates Bench International* Bente Hansen & Associates Berkshire Hathaway Home Services* Bionest Partners Biosources BioSurplus Biotech Primer Biotech Vending BioTix Blue Sky Broadcast

Bootstrap Incubation Caliber Associates California Commercial Security Cambridge Research Biochemicals* Canteen Vending Services CBRE China Business Partners Chubb Group of Insurance Companies Clinigen Healthcare Controlled Contamination Services Corning* Covisint Corporation* Cox Business CSCI Cymer Domain Associates EBD Group Elsevier Enterey EquipNet Euretos Exp U.S. Services Ferguson Pape Baldwin Architects Fisher & Phillips Forward Ventures Fragomen, Del Rey, Bernsen & Loewy French Biobeach Frequentz Gable PR Gamxing* Gensler

G/M Business Interiors* Grande Colonial Grant Thornton Hartl Team- Private Banking & Investment Group- Merrill Lynch* Haworth* HCP Life Science Estates H.G. Fenton Company Hyatt Regency La Jolla at Aventine IBM Life Sciences* Innovative Commercial Environments Innovative Lease Services J.T. MacMillan Photography Jackson & Blanc HVAC Contractors Jones Lang LaSalle Kilroy Realty Knobbe, Martens, Olson & Bear Leadership Edge Legacy Partners Commercial Managed Solution Mayer Hoffman McCann McKenna Long & Aldridge Medidata Solutions* Medline Industries* Mehlman Barnes* Mercury Fund* Morgan, Lewis & Bockius Morrison & Foerster Occupational Services Office Depot

Ogletree, Deakins, Nash, Smoak & Stewart Orion International Patent Office* Outlier Solutions Oxford Finance Pharmalink Consulting PR Newswire Prevost Construction Procopio, Cory, Hargreaves & Savitch Project Management Advisors Relocation Coordinates Retirement DNA San Diego World Trade Center Sartorius SecureDocs Scient Federal Credit Union Sharp Business Systems Sheppard Mullin Richter & Hampton Shred San Diego Signature Analytics Silicon Valley Bank SLM Group Sofinnova Ventures Sonceboz Corporation Square 1 Bank S Squared Executive Search Stradling Yocca Carlson & Rauth Savills Studley Sughrue Mion Synergy Corporate Housing Tata America International

Technical Safety Services The Business Cleaning Company The HealthEd Group The Sandler Group Thomas, Mcnerney & Partners Time Warner Cable* T-Mobile USA United Parcel Service (UPS) VDP Direct Veolia Virgin America WCCT Global

* New Members from May 2014 to October 2014

CIA substantiates your claim at FDA.

Mediconomics – expertise since 1999 Clinical Research Regulatory Affairs Medical Devices Medical Writing Pharmacovigilance Product Development Data Management

Mediconomics – strategy: Innovative solutions for value dossiers Tailor-made tools for regulatory processes Pharmacovigilance solutions

Clinical Intelligence Agency (CIA) Mediconomics is a Clinical Intelligence Agency and a premier provider of high quality clinical services. Our extensive capabilities have been serving the medical industry since 1999.

Worldwide network Mediconomics‘ headquarters is located in Germany where the company is one of the biggest CROs and has subsidiaries in Los Angeles (USA) and in close proximity to London (UK). Additional affiliate companies cover Austria, Switzerland and Scandinavia, making it an enterprise acting throughout Europe.

Skillfull accuracy Whilst being 1/3 more cost-efficient than US-companies we utilize our German professionalism to achieve your targets within time and budget.

Our team represents a consummate balance of science and business, which allows us to achieve clinical excellence, technological innovation and bottom-line productivity, always maintaining the highest quality standards.

Call +1 (619) 213-9657 and we will talk to you.

Mail to info@mediconomics.com or visit www.mediconomics.com

mediconomics gmbh · Hannover · Germany · mediconomics inc. · Los Angeles · USA · mediconomics UK · Staffordshire · UK

9393 Towne Centre Drive, #200 San Diego, CA 92121-3021 www.Biocom.org Please send a change of address or subscription request to Arlene Arreola at aarreola@Biocom.org.

Achieve Achieve professional success through Life Achieveprofessional professionalsuccess successthrough throughLife Life Science Science continuing education programs.

Sciencecontinuing continuingeducation educationprograms. programs.

Through Through cutting-edge cutting-edge certificates certificates and and courses, courses, UCUC San San Diego Diego Extension’s Extension’s professional professional Through cutting-edge certificates and courses, UC San Diego Extension’s professional development development programs programs enhance enhance skills skills development development in in critical critical LifeLife Sciences Sciences occupations. occupations. development programs enhance skills development in critical Life Sciences occupations.

Choose Choose from from a wide a wide variety variety of of classes classes and and programs programs attracting attracting both both individuals individuals and and Choose from a wide variety of classes and programs attracting both individuals and organizations organizations alike. alike. organizations alike.

Explore Explore LifeLife Sciences Sciences programs programs in:in: Explore Life Sciences programs in: • •Biostatistics Biostatistics & Data & Data Analytics Analytics • •Intellectual Intellectual Property Property • Biostatistics & Data Analytics • Intellectual Property • •Biotechnology Biotechnology Project Project Management Management • •LifeLife Sciences Sciences IT IT • Biotechnology Project Management • Life Sciences IT • •Diagnostics Diagnostics • •Medicinal Medicinal Chemistry Chemistry • Diagnostics • Medicinal Chemistry • •Drug Drug Discovery/ADMET Discovery/ADMET • •Quality Quality Assurance Assurance and and Control Control • Drug Discovery/ADMET • Quality Assurance and Control • •Industrial Industrial Biotechnology Biotechnology • •Regulatory Regulatory Affairs Affairs • Industrial Biotechnology • Regulatory Affairs (Biofuels, (Biofuels, Fermentation) Fermentation) (Biofuels, Fermentation)

Ready Ready Bio fuel fuel your career?

Readytoto toBio Bio fuelyour yourcareer? career?

Start Start this this January January with with these these Specialized Specialized Certificates!

Certificates!

Start this January with these Specialized Certificates!

Biofuels Biofuels Science Science Biofuels Science • Hands • Hands onon experience experience • Hands on experience • Focused • Focused training training forfor field field andand laboratory laboratory roles roles • Focused training for field and laboratory roles • Online • Online lectures lectures andand summer summer lablab experience experience at at • Online lectures and summer lab experience at UCUC SanSan Diego Diego campus campus UC San Diego campus Biofuels Biofuels Processes Processes Biofuels Processes • Offered • Offered completely completely ONLINE ONLINE • Offered completely ONLINE • Designed • Designed forfor management-track management-track professionals professionals • Designed for management-track professionals • Examination • Examination of of Biofuels Biofuels research, research, production, production, analysis analysis • Examination of Biofuels research, production, analysis andand downstream downstream processing processing and downstream processing Developed Developed in partnership in partnership with with Developed in partnership with

ForFor your your convenience, convenience, many many of of ourour certificates certificates and and courses courses areare offered offered online! online!

For your convenience, many of our certificates and courses are offered online!

ForFor more more information: information: (858) (858) 534-9353 534-9353 | unexbio@ucsd.edu | unexbio@ucsd.edu | extension.ucsd.edu/lifesciences | extension.ucsd.edu/lifesciences For more information: (858) 534-9353 | unexbio@ucsd.edu | extension.ucsd.edu/lifesciences